207 related articles for article (PubMed ID: 36151773)
21. A phase 1 study of entinostat in children and adolescents with recurrent or refractory solid tumors, including CNS tumors: Trial ADVL1513, Pediatric Early Phase-Clinical Trial Network (PEP-CTN).
Bukowinski A; Chang B; Reid JM; Liu X; Minard CG; Trepel JB; Lee MJ; Fox E; Weigel BJ
Pediatr Blood Cancer; 2021 Apr; 68(4):e28892. PubMed ID: 33438318
[TBL] [Abstract][Full Text] [Related]
22. [Irinotecan plus temozolomide in refractory or relapsed pediatric solid tumors].
Hernández-Marqués C; Lassaletta-Atienza A; Ruiz Hernández A; Blumenfeld Olivares JA; Arce Abaitua B; Cormenzana Carpio M; Madero Lopez L
An Pediatr (Barc); 2013 Aug; 79(2):68-74. PubMed ID: 23332825
[TBL] [Abstract][Full Text] [Related]
23. Regorafenib plus Vincristine and Irinotecan in Pediatric Patients with Recurrent/Refractory Solid Tumors: An Innovative Therapy for Children with Cancer Study.
Casanova M; Bautista F; Campbell-Hewson Q; Makin G; Marshall LV; Verschuur AC; Cañete Nieto A; Corradini N; Ploeger BA; Brennan BJ; Mueller U; Zebger-Gong H; Chung JW; Geoerger B
Clin Cancer Res; 2023 Nov; 29(21):4341-4351. PubMed ID: 37606641
[TBL] [Abstract][Full Text] [Related]
24. Efficacy of the VIT (vincristine, irinotecan and temozolomide) regimen in adults with metastatic Ewing sarcoma.
Dogan I; Iribas A; Ahmed MA; Basaran M
J Chemother; 2023 Jul; 35(4):343-347. PubMed ID: 35894948
[TBL] [Abstract][Full Text] [Related]
25. [Chemotherapy in patients with refractory Ewing sarcoma].
Raciborska A; Bilska K; Drabko K; Rogowska E; Chaber R; Pogorzała M; Wyrobek E; Połczyńska K; Rodriguez-Galindo C; Woźniak W
Med Wieku Rozwoj; 2013; 17(2):117-25. PubMed ID: 23988368
[TBL] [Abstract][Full Text] [Related]
26. A phase 1 study of simvastatin in combination with topotecan and cyclophosphamide in pediatric patients with relapsed and/or refractory solid and CNS tumors.
Cash T; Jonus HC; Tsvetkova M; Beumer JH; Sadanand A; Lee JY; Henry CJ; Aguilera D; Harvey RD; Goldsmith KC
Pediatr Blood Cancer; 2023 Aug; 70(8):e30405. PubMed ID: 37158620
[TBL] [Abstract][Full Text] [Related]
27. Anlotinib, Vincristine, and Irinotecan for Advanced Ewing Sarcoma After Failure of Standard Multimodal Therapy: A Two-Cohort, Phase Ib/II Trial.
Xu J; Xie L; Sun X; Liu K; Tang X; Yan T; Yang R; Guo W; Gu J
Oncologist; 2021 Jul; 26(7):e1256-e1262. PubMed ID: 33611805
[TBL] [Abstract][Full Text] [Related]
28. A phase I study of irinotecan in combination with metronomic temozolomide in patients with recurrent glioblastoma.
Reynés G; Balañá C; Gallego O; Iglesias L; Pérez P; García JL
Anticancer Drugs; 2014 Jul; 25(6):717-22. PubMed ID: 24322542
[TBL] [Abstract][Full Text] [Related]
29. VIncristine, irinotecan, and temozolomide in children and adolescents with relapsed rhabdomyosarcoma.
Setty BA; Stanek JR; Mascarenhas L; Miller A; Bagatell R; Okcu F; Nicholls L; Lysecki D; Gupta AA
Pediatr Blood Cancer; 2018 Jan; 65(1):. PubMed ID: 28748602
[TBL] [Abstract][Full Text] [Related]
30. Irinotecan and temozolomide chemotherapy in paediatric and adult populations with relapsed Ewing Sarcoma.
Salah S; To YH; Khozouz O; Ismail T; Yaser S; Alnsour A; Shahin O; Sultan I; Abuhijlih R; Halalsheh H; Abuhijla F; Lewin J
Clin Transl Oncol; 2021 Apr; 23(4):757-763. PubMed ID: 32761317
[TBL] [Abstract][Full Text] [Related]
31. Phase I and pharmacokinetic study of cetuximab and irinotecan in children with refractory solid tumors: a study of the pediatric oncology experimental therapeutic investigators' consortium.
Trippett TM; Herzog C; Whitlock JA; Wolff J; Kuttesch J; Bagatell R; Hunger SP; Boklan J; Smith AA; Arceci RJ; Katzenstein HM; Harbison C; Zhou X; Lu H; Langer C; Weber M; Gore L
J Clin Oncol; 2009 Oct; 27(30):5102-8. PubMed ID: 19770383
[TBL] [Abstract][Full Text] [Related]
32. Temozolomide and intravenous irinotecan for treatment of advanced Ewing sarcoma.
Wagner LM; McAllister N; Goldsby RE; Rausen AR; McNall-Knapp RY; McCarville MB; Albritton K
Pediatr Blood Cancer; 2007 Feb; 48(2):132-9. PubMed ID: 16317751
[TBL] [Abstract][Full Text] [Related]
33. A phase I window, dose escalating and safety trial of metformin in combination with induction chemotherapy in relapsed refractory acute lymphoblastic leukemia: Metformin with induction chemotherapy of vincristine, dexamethasone, PEG-asparaginase, and doxorubicin.
Trucco M; Barredo JC; Goldberg J; Leclerc GM; Hale GA; Gill J; Setty B; Smith T; Lush R; Lee JK; Reed DR
Pediatr Blood Cancer; 2018 Sep; 65(9):e27224. PubMed ID: 29856514
[TBL] [Abstract][Full Text] [Related]
34. A phase I trial of talazoparib and irinotecan with and without temozolomide in children and young adults with recurrent or refractory solid malignancies.
Federico SM; Pappo AS; Sahr N; Sykes A; Campagne O; Stewart CF; Clay MR; Bahrami A; McCarville MB; Kaste SC; Santana VM; Helmig S; Gartrell J; Shelat A; Brennan RC; Hawkins D; Godwin K; Bishop MW; Furman WL; Stewart E
Eur J Cancer; 2020 Sep; 137():204-213. PubMed ID: 32795876
[TBL] [Abstract][Full Text] [Related]
35. A pediatric phase 1 trial of vorinostat and temozolomide in relapsed or refractory primary brain or spinal cord tumors: a Children's Oncology Group phase 1 consortium study.
Hummel TR; Wagner L; Ahern C; Fouladi M; Reid JM; McGovern RM; Ames MM; Gilbertson RJ; Horton T; Ingle AM; Weigel B; Blaney SM
Pediatr Blood Cancer; 2013 Sep; 60(9):1452-7. PubMed ID: 23554030
[TBL] [Abstract][Full Text] [Related]
36. Dose escalation of intravenous irinotecan using oral cefpodoxime: a phase I study in pediatric patients with refractory solid tumors.
McGregor LM; Stewart CF; Crews KR; Tagen M; Wozniak A; Wu J; McCarville MB; Navid F; Santana VM; Houghton PJ; Furman WL; Rodriguez-Galindo C
Pediatr Blood Cancer; 2012 Mar; 58(3):372-9. PubMed ID: 21509928
[TBL] [Abstract][Full Text] [Related]
37. Combination of bevacizumab, irinotecan, and temozolomide for refractory or relapsed neuroblastoma: Results of a phase II study.
Modak S; Kushner BH; Basu E; Roberts SS; Cheung NK
Pediatr Blood Cancer; 2017 Aug; 64(8):. PubMed ID: 28111925
[TBL] [Abstract][Full Text] [Related]
38. Phase I trial of dasatinib, lenalidomide, and temozolomide in children with relapsed or refractory central nervous system tumors.
Robison NJ; Yeo KK; Berliner AP; Malvar J; Sheard MA; Margol AS; Seeger RC; Rushing T; Finlay JL; Sposto R; Dhall G
J Neurooncol; 2018 May; 138(1):199-207. PubMed ID: 29427149
[TBL] [Abstract][Full Text] [Related]
39. Irinotecan dose schedule for the treatment of Ewing sarcoma.
Slotkin EK; Meyers PA
Pediatr Blood Cancer; 2023 Jan; 70(1):e30005. PubMed ID: 36184748
[TBL] [Abstract][Full Text] [Related]
40. Phase I study of vincristine, irinotecan, and ¹³¹I-metaiodobenzylguanidine for patients with relapsed or refractory neuroblastoma: a new approaches to neuroblastoma therapy trial.
DuBois SG; Chesler L; Groshen S; Hawkins R; Goodarzian F; Shimada H; Yanik G; Tagen M; Stewart C; Mosse YP; Maris JM; Tsao-Wei D; Marachelian A; Villablanca JG; Matthay KK
Clin Cancer Res; 2012 May; 18(9):2679-86. PubMed ID: 22421195
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
